Solely to remove it from the existing pharmaceutical company paradigm where manufacturing is probably not prioritised relative to drug development / marketing / sales. Hard to find capital for expansion of facilities if it being used up buying large, expensive, unprofitable drug portfolios...
Ann: NEXTSTELLIS FDA exclusivity & phase III data published, page-32
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.07 |
Change
0.050(1.00%) |
Mkt cap ! $411.9M | |||
| Open | High | Low | Value | Volume |
| $5.00 | $5.14 | $4.94 | $712.4K | 141.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1059 | $5.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.13 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |